US Patent and Trademark Office Concludes Rulings on 11

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
US Patent and Trademark Office Concludes Rulings on 11 Petitions for Inter Partes Review by Symantec Against 8 Finjan Patents

EAST PALO ALTO, CA--(Marketwired - Mar 21, 2016) - Finjan Holdings, Inc. (NASDAQ: FNJN), a cybersecurity company, announced that on March 18, 2016, the Patent Trial and Appeal Board (PTAB) for the United States Patent & Trademark Office (USPTO) concluded its rulings on Symantec Corporation's attempts to invalidate 8 of subsidiary, Finjan, Inc.'s patents through Inter Partes Review ("IPR"), that Finjan accuses Symantec of infringing in the U.S. District Court for the Northern District of California (Finjan v. Symantec, 3-14-cv-02998-HSG). Symantec attempted to invalidate all 8 of the asserted Finjan's patents through 11 separate IPR challenges. The PTAB rejected 10 of the 11 challenges, or 30 of 31 grounds of invalidity sought by Symantec. 

The most recent decisions took place on March 11, 2016 when the PTAB denied institution of IPRs (IPR2015-01893 and IPR2015-01894) on Finjan's US Patent Nos. 7,613,926 ("the '926 Patent"), and 6,154,844 ("the '844 Patent"), respectively, finding Symantec had failed to establish a reasonable likelihood that it would prevail at trial in showing either the '926 or the '844 Patents are invalid. With respect to IPR2015-01892 (US Patent No. 8,677,494 or "the '494 Patent"), on March 18, the PTAB granted institution of trial to hear evidence of whether certain '494 Patent claims are invalid in light of prior art. Reference to the previous PTAB decisions can be found on Finjan's press release site [See, Finjan's Core Patents Further Strengthened by US Patent & Trademark Office, February 29, 2016 and US Patent Office Rejects Review on Six of Symantec's Petitions for Inter Partes Review Challenging Five of Finjan's Patents Asserted Against Symantec, January 14, 2016.]

"We applaud the PTAB's thoroughness in reviewing the onslaught of IPRs brought by Symantec and are gratified with the results we have thus far been able to achieve," commented Julie Mar-Spinola, Finjan Holding's Chief IP Officer. "We will vigorously defend the '494 Patent before the PTAB and establish that Finjan invented the claimed subject matter first. Further, we believe the PTAB's findings support the general strength, value, and relevance of Finjan's patents and should simplify the issues for the District Court trial."

Final summary of Symantec IPR challenges against Finjan Patents:

  • '154 Patent - IPR2015-01547: 4 Grounds; all denied
  • '182 Patent - IPR2015-01548: 2 Grounds; all denied
  • '289 Patent - IPR2015-01552: 2 Grounds; all denied
  • '299 Patent - IPR2015-01549: 2 Grounds; all denied
  • '494 Patent - IPR2015-01892: 4 Grounds; 3 denied, 1 instituted
  • '494 Patent - IPR2015-01897: 4 Grounds; all denied
  • '844 Patent - IPR2015-01894: 3 Grounds; all denied
  • '926 Patent - IPR2015-01893: 2 Grounds; all denied
  • '926 Patent - IPR2015-01895: 2 Grounds; all denied
  • '996 Patent - IPR2015-01545: 4 Grounds; all denied
  • '996 Patent - IPR2015-01546: 2 Grounds; all denied

Finjan also has pending infringement lawsuits against FireEye, Inc., Proofpoint Inc., Sophos, Inc., Palo Alto Networks, Inc., and Blue Coat Systems, Inc. relating to, collectively, more than 20 patents in the Finjan portfolio. The court dockets for the foregoing cases are publicly available on the Public Access to Court Electronic Records (PACER) website, www.pacer.gov, which is operated by the Administrative Office of the U.S. Courts.

ABOUT FINJAN
Established nearly 20 years ago, Finjan is a globally recognized leader in cybersecurity. Finjan's inventions are embedded within a strong portfolio of patents focusing on software and hardware technologies capable of proactively detecting previously unknown and emerging threats on a real-time, behavior-based basis. Finjan continues to grow through investments in innovation, strategic acquisitions, and partnerships promoting economic advancement and job creation. For more information, please visit www.finjan.com.

Follow Finjan Holdings, Inc.:
Twitter: @FinjanHoldings
LinkedIn: linkedin.com/company/finjan

Cautionary Note Regarding Forward-Looking Statements
Except for historical information, the matters set forth herein that are forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. Potential risks and uncertainties include, but are not limited to, Finjan's expectations and beliefs regarding Finjan's licensing program, the outcome of pending or future enforcement actions, the granting of Inter Partes Review (IPR) of our patents or an unfavorable determination pursuant to an IPR or other challenges at the USPTO of our patents, the enforceability of our patents, our ability to expand our technology and patent portfolio, the continued use of our technologies in the market, our stock price, changes in the trading market for our securities, regulatory developments, general economic and market conditions, the market acceptance and successful business, technical and economic implementation of Finjan Holdings' intended operational plan; and the other risk factors set forth from time to time in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2014, and the Company's periodic filings with the SEC, copies of which are available free of charge at the SEC's website at www.sec.gov or upon request from Finjan Holdings, Inc. All forward-looking statements herein reflect our opinions only as of the date of this release. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Finjan Holdings undertakes no obligation, and expressly disclaims any obligation, to update forward-looking statements herein in light of new information or future events.

Media Contact:
Nicholas Gaffney
Zumado Public Relations
(415) 732-7801
ngaffney@zumado.com

Investor Contact:
Alan Sheinwald or Valter Pinto
Capital Markets Group LLC
Vanessa Winter
Finjan
(650) 282-3245
investors@finjan.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 127

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod

Updated Category News Views 5

A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 271

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 13

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 71

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 30

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 292

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
Skanska Adds $80M U.S. Tech Facility Contract to Orders

Updated Category News Views 107

An $80 million add-on is the sort of construction news that looks modest until you remember what it says about the customer relationship. Skanska has won an additional contract from an existing client for a U.S. tech facility, worth roughly SEK 760 million, and it will enter U.S. order bookings in the fourth quarter of 2026. No fireworks, no grand strategic...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 165

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 107

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading

Top 5 Most Recently Viewed Articles

Prinses Máxima Center Enhances Genomics with Callisto™ Innovation

Updated Category News Views 300

Prinses Máxima Center's Partnership with Volta Labs The Prinses Máxima Center for Pediatric Oncology is making headlines with its recent acquisition of the Callisto™ platform from Volta Labs. This major step forward aims to enhance efficiency in sample preparation across a variety of genomics workflows, specifically designed for both Illumina and Oxford Nanopore...

Continue Reading
Keros Therapeutics to Showcase Innovations at Key Conferences

Updated Category News Views 152

Exciting Participation of Keros Therapeutics in Major Conferences Keros Therapeutics, Inc. is making significant strides in the biopharmaceutical landscape by focusing on innovative therapies targeting disorders associated with the TGF-ß family of proteins. Recently, the company announced that its Chair and Chief Executive Officer, Jasbir S. Seehra, Ph.D., will represent...

Continue Reading
KULR Technology Unveils Major Licensing Breakthrough with Japan

Updated Category News Views 133

KULR Technology Group, Inc. (NYSE American: KULR) unveiled a major licensing agreement back in 2024 that had traders buzzing. This $2.35 million deal centered around their vibration reduction technology, known as KULR Xero Vibe (KXV). At first glance, it seemed like a solid step for the company into new markets, but let’s peel back the layers and see what's really...

Continue Reading
Mainz Biomed Achieves Significant Milestones and Results

Updated Category News Views 204

Mainz Biomed Reports Financial Results and Strategic Progress Lab network revenue up by 33% year-over-year. Operating loss down by 30% and net loss by 18%. Partnerships driving innovation and growth forward. Highlighting 2025 accomplishments and future goals. Mainz Biomed N.V. (NASDAQ: MYNZ), a pioneering molecular genetics diagnostic firm, has reported its financial...

Continue Reading
PioCreat Launches Innovative Mini Dental 3D Printer During Expo

Updated Category News Views 247

PioCreat Launches Innovative Mini Dental 3D Printer at Moscow Event PioCreat, a well-respected name in the 3D printing sector, made a significant impression at the dental industry's notable event, the 2025 Moscow Dental Expo. This gathering, renowned for showcasing advancements in digital dentistry, took place at Crocus-Expo IEC, attracting a wide array of international...

Continue Reading